De Vries M H, Van Harten J, Van Bemmel P, Raghoebar M
Clinical R&D Solvay Duphar B.V., Weesp, The Netherlands.
Biopharm Drug Dispos. 1993 May;14(4):291-6. doi: 10.1002/bdd.2510140403.
The pharmacokinetics of fluvoxamine after single oral administration of 25, 50, and 100 mg fluvoxamine maleate was studied in a three-way cross-over study in 12 healthy male subjects. Fluvoxamine was administered orally in a solution. For dose-proportionality, AUC, and Cmax-dose relationships were evaluated by linear regression. Plasma concentrations increased in a linear dose-dependent manner in the dose range between 25 and 100 mg; t1/2 and Tmax showed no significant differences among treatments. Fluvoxamine was well tolerated.
在一项针对12名健康男性受试者的三交叉研究中，研究了单次口服25毫克、50毫克和100毫克马来酸氟伏沙明后氟伏沙明的药代动力学。氟伏沙明以溶液形式口服给药。为评估剂量比例、AUC和Cmax与剂量的关系，采用线性回归分析。在25至100毫克的剂量范围内，血浆浓度呈线性剂量依赖性增加；各治疗组间t1/2和Tmax无显著差异。氟伏沙明耐受性良好。
